Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL28182316 | 0.98 | HPGD (0.54) | HPGDRECQLMEN1KMT2ANPC1 | |
| SCHEMBL1515203 | 0.94 | HPGD (0.49) | HPGDRECQLMEN1KMT2ANPC1 | |
| SCHEMBL1515445 | 0.90 | SMN1; SMN2 (0.48) | HPGDRECQLSMN1; SMN2KDM4EHRH3 | |
| SCHEMBL6398671 | 0.87 | HPGD (0.48) | HPGDRECQLMEN1KMT2ANPC1 | |
| SCHEMBL13208093 | 0.86 | HRH3 (0.46) | HPGDRECQLMEN1KMT2ANPC1 | |
| SCHEMBL6400570 | 0.86 | HPGD (0.47) | HPGDRECQLMEN1KMT2ANPC1 | |
| SCHEMBL6399683 | 0.84 | HPGD (0.46) | HPGDRECQLMEN1KMT2ANPC1 | |
| SCHEMBL21078184 | 0.83 | GBA1 (0.49) | HPGDRECQLMEN1KMT2ANPC1 | |
| Piperidine SCHEMBL5689680 | 0.83 | GBA1 (0.49) | HPGDRECQLMEN1KMT2ANPC1 | |
| SCHEMBL29520963 | 0.81 | GBA1 (0.55) | SMN1; SMN2KDM4EHRH3HRH1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025129233-A1 | ELECTROCHEMICAL REACTIONS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2025-06-26 | — | — | WO | claimed |
| CN-104903312-B | RHO kinase inhibitor | 卡德门企业有限公司 | 2019-01-29 | — | — | CN | claimed |
| CN-108802211-A | The liquid phase detection method of related substances in a kind of Cefquinome sulfate breast injection | 佛山市南海东方澳龙制药有限公司 | 2018-11-13 | — | — | CN | claimed |
| CN-108802212-A | A kind of liquid phase detection method of lactation period Cefquinome sulfate breast injection related substances | 佛山市南海东方澳龙制药有限公司 | 2018-11-13 | — | — | CN | claimed |
| CN-104511271-B | A kind of molecular sieve, its manufacture method and its application | 中国石油化工股份有限公司 | 2017-12-15 | — | — | CN | claimed |
| CN-105101996-A | Treatment of ocular disorders | KADMON CORP LLC | 2015-11-25 | — | — | CN | claimed |
| CN-104903312-A | RHO KINASE INHIBITORS | KADMON CORP LLC | 2015-09-09 | — | — | CN | claimed |
| WO-2025129233-A1 | ELECTROCHEMICAL REACTIONS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2025-06-26 | — | — | WO | disclosed |
| CN-110461842-A | FUSED PENTACYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL | 2019-11-15 | — | — | CN | disclosed |
| CN-107108672-B | Condensed five rings imdazole derivatives | UCB生物制药私人有限公司 | 2019-11-08 | — | — | CN | disclosed |
| CN-110325522-A | Liquid crystal compounds | 默克专利股份有限公司 | 2019-10-11 | — | — | CN | disclosed |
| CN-109996791-A | Single fluorination hexamethylene | 默克专利股份有限公司 | 2019-07-09 | — | — | CN | disclosed |
| CN-109863226-A | Nano capsule comprising liquid crystal media | 默克专利股份有限公司 | 2019-06-07 | — | — | CN | disclosed |
| US-8415336-B2 | Cyclic (aza)indolizinecarboxamides, their preparation and their use as pharmaceuticals | SANOFI (FR) | 2013-04-09 | — | — | US | disclosed |
| US-20120232081-A1 | CYCLIC (AZA)INDOLIZINECARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2012-09-13 | — | — | US | disclosed |
| US-20120142932-A1 | METHOD FOR MANUFACTURING 4-(5-METHYLPYRIDIN-2-YLAMINO)PIPERIDINE-1-CARBOXYLIC ACID DERIVATIVE | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| EP-2459557-A1 | CYCLIC (AZA)INDOLIZINECARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2012-06-06 | — | — | EP | disclosed |
| CN-102471339-A | Pyrrolopyridine inhibitors of kinases | ABBOTT LAB | 2012-05-23 | — | — | CN | disclosed |
| US-5622953-A | DRUG RESISTANT TO ANTICANCER CHEMOTHERAPEUTIC DRUG | BASF AKTIENGESELLSCHAFT (DE) | 1997-04-22 | — | — | US | disclosed |
| WO-1994022842-A1 | 1-AMINO-3-PHENOXY PROPANE DERIVATIVES AS MODULATORS OF MULTI-DRUG RESISTANCE | BASF AKTIENGESELLSCHAFT (DE) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142932-A1 | METHOD FOR MANUFACTURING 4-(5-METHYLPYRIDIN-2-YLAMINO)PIPERIDINE-1-CARBOXYLIC ACID DERIVATIVE | PAH, ALK, ADSL | HPGD 2741/4885RECQL 4542/4885MEN1 2750/4885 |
| US-20120232081-A1 | CYCLIC (AZA)INDOLIZINECARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | REN, ACE, PM20D2 | HPGD 664/4885RECQL 152/4885MEN1 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.